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Shrinkage estimation in a meta-analysis framework may be used to facilitate dynamical borrowing of infor-
mation. This framework might be used to analyze a new study in the light of previous data, which might
differ in their design (e.g., a randomized controlled trial (RCT) and a clinical registry). We show how the
common study weights arise in effect and shrinkage estimation, and how these may be generalized to the
case of Bayesian meta-analysis. Next we develop simple ways to compute bounds on the weights, so that the
contribution of the external evidence may be assessed a priori. These considerations are illustrated and dis-
cussed using numerical examples, including applications in the treatment of Creutzfeldt-Jakob disease and
in fetal monitoring to prevent the occurrence of metabolic acidosis. The target study’s contribution to the re-
sulting estimate is shown to be bounded below. Therefore, concerns of evidence being easily overwhelmed
by external data are largely unwarranted.
Key words: Random-effects meta-analysis; Bayesian statistics; Between-study heterogeneity;
Shrinkage estimation; Inverse-variance weights.
1 Introduction
In some situations it is useful to support an estimate using additional external evidence, for example, when
a small study in the context of a rare disease may be supplemented with data from a clinical registry or
electronic health records, or when the result from a meta-analysis may be backed by an analysis in a sim-
ilar field, e.g., a related but somewhat different population. The involved data contributions then take on
different roles, namely, that of a source (the external data) and a target (the data of primary interest). Dy-
namic borrowing refers to the class of approaches where the apparent, empirical similarity or compatibility
of the source and the target is taken into account when judging to what degree the two should be lumped
together (Ro¨ver and Friede, 2020). Such approaches may be implemented, e.g., via hierarchical models
or informative priors; both are actually equivalent to some degree in the context of the normal-normal
hierarchical model (NNHM) (Schmidli et al., 2014). Similarly, closely related (or partly equivalent) ap-
proaches are given by the bias allowance framework (Welton et al., 2012) or the power prior framework
(Ibrahim and Chen, 2000). A recent example of such an approach is given by the EARLY PRO-TECT trial in
paediatric Alport disease, where data from a randomized controlled trial (RCT) were supported by source
data from an open-label arm and a clinical registry (Gross et al., 2020).
In the context of dynamic borrowingwithin the NNHM framework, the flow of information is quite com-
monly illustrated by quotingweights of data sources as these are combined to a joint estimate. As the even-
tual estimate may be expressed as a weighted average of the input data, the correspondingweights are a use-
ful means of quantifying the studies’ contributions to or influence on the eventual result (Hedges and Olkin,
1985; Hartung et al., 2008). Analogous weights arise for shrinkage estimates (Raudenbush and Bryk,
1985; Robinson, 1991; Viechtbauer, 2010), and, as we will show below, also in the Bayesian paradigm
with prior distributions on effect and heterogeneity parameters.
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When combining originally separate data sets in a meta-analysis or using shrinkage estimation, there
sometimes is concern that evidence from the target data may be overwhelmed by a much larger set of source
data, e.g., when combining a small RCT with a large clinical registry or routine data (e.g. electronic health
records) (Weber et al., 2018). In such cases it is instructive to explicate the notion of study contributions by
considering their weights. Again, we can see the dynamic nature of the approach in the changing weight
of external data with varying data compatibility or discrepancy. It turns out that within the Bayesian
framework we can determine the minimum weight of the target study (the RCT in the above example)
a priori for a given analysis, and with that we are able to provide more insights into the general behaviour
of the meta-analysis procedure. The derived formulas show shrinkage estimation to behave reasonably and
also predictably.
In the following, we will introduce the NNHM, and show how “study weights” arise in effect and
shrinkage estimation and how the concept may be extended to the Bayesian framework. Then we take a
closer look at the weights’ properties and show how these may be bounded across possible prior settings
and/or data realisations. The arguments are illustrated by a numerical study, and the ideas are employed in
two example applications involving the joint analysis of a “small” target and a “large” source study, as well
as two equally-sized studies. Due to the few-study setup (Friede et al., 2017b; Ro¨ver and Friede, 2020),
we will be focusing on Bayesian methods and only in between point out some connections to common
analogous frequentist results. We close with a discussion of the findings and their practical implications.
2 The normal-normal hierarchical model (NNHM)
The NNHM models a set of k estimates yi and their standard errors σi as
yi|θi, σi ∼ Normal(θi, σ
2
i ), (1)
where θi are the study-specific effects. The θi are not necessarily identical for all studies, but they are also
associated with a certain amount of variation, expressed as
θi|µ, τ ∼ Normal(µ, τ
2). (2)
The mean parameter µ is the overall mean effect, while τ denotes the between-study variability (hetero-
geneity). As noted elsewhere (Hedges and Olkin, 1985; Hartung et al., 2008; Ro¨ver, 2020), marginalizing
over the parameters θi, the model may be written as
yi|µ, τ, σi ∼ Normal(µ, σ
2
i + τ
2). (3)
The NNHM is a random-effects (RE) model, which in the special case of τ = 0 reduces to a fixed-effect
(FE) (or common-effect)model. It provides a good approximation for many types of effect measures where
measurement uncertainty and between-study variability may be assumed to be (approximately) normally
distributed (Jackson and White, 2018). Data analysis may then aim at estimating the overall effect µ or
study-specific effects θi (“shrinkage estimation”); in the present investigation, we will mostly be concerned
with the latter.
In the following, we will denote vectors of effect estimates (y1, . . . , yk) and their standard errors
(σ1, . . . , σk) by ~y and ~σ, respectively. Furthermore, we will be mostly concerned with the special case of
only two studies (k = 2) and a non-informative (improper) uniform prior for the overall effect (p(µ) ∝ 1).
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3 Study weights
3.1 Conditional weights
Assuming an (improper) uniform prior for the overall effect µ, the conditional posterior distribution of µ
(given τ ) is normal with mean
µ˜(τ) = E[µ|τ, ~y, ~σ] =
k∑
i=1
wi(τ) yi, (4)
where the inverse variance (IV) weights wj(τ) are given by
wj(τ) =
1
σ2
j
+τ2∑k
i=1
1
σ2
i
+τ2
(5)
as in the frequentist framework (Hedges and Olkin, 1985; Hartung et al., 2008; Friede et al., 2017a). A
similar formula also applies for a normal effect prior (Ro¨ver, 2020). These two (conditionally conjugate)
priors are computationally simple, readily motivated and with that probably also the two most commonly
used ones.
The conditional posterior of the study-specific effect θj (the shrinkage estimate) is also normal with its
mean θ˜j(τ) depending on yi and µ˜(τ), namely
θ˜j(τ) = E[θj|τ, ~y, ~σ] = bj(τ) yj +
(
1− bj(τ)
)
µ˜(τ) (6)
where the corresponding weight (Ro¨ver, 2020; Wandel et al., 2017) is
bj(τ) =
1
σ2
j
1
σ2j
+ 1
τ2
. (7)
The formulation in (6) shows to which degree the estimate is shrunk towards the common overall mean µ˜(τ)
(depending on the amount of heterogeneity). Equation (6) may be re-written as
θ˜j(τ) =
[
bj(τ) +
(
1− bj(τ)
)
wj(τ)
]
yj +
∑
i6=j
[(
1− bj(τ)
)
wi(τ)
]
yi (8)
= cjj(τ) yj +
∑
i6=j
cij(τ) yi (9)
=
k∑
i=1
cij(τ) yi (10)
so that the actual shrinkage weights cij(τ) (of the ith study for the jth shrinkage estimate) become more
explicit. In the special case of only two studies (k = 2), the coefficients cij(τ) simplify to
c11(τ) =
σ22 + 2τ
2
σ21 + σ
2
2 + 2τ
2
, c12(τ) =
σ21
σ21 + σ
2
2 + 2τ
2
, (11)
and analogously for c22 and c21.
The conditional mean µ˜(τ) commonly also arises in frequentist approaches as an overall effect estima-
tor, where usually a heterogeneity estimate τˆ is plugged in for τ (Hedges and Olkin, 1985; Hartung et al.,
2008). Similarly, θ˜j(τ) is commonly used for “best linear unbiased prediction (BLUP)” (Raudenbush and Bryk,
1985; Robinson, 1991; Viechtbauer, 2010). The weights (wj(τ) or cij(τ)) are then often quoted along with
the results in order to illustrate the individual studies’ contributions to the overall result. Note that while
weights may be appealing, they still constitute an ultimately somewhat heuristic notion of the concept of a
study’s contribution.
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3.2 Marginal weights
In a Bayesian multiparameter model, the conditional expectations (of effects µ or θj) as derived above
are commonly of limited interest; what is usually more interesting are the marginal posterior expectations,
as these refer to the posterior distribution integrated over other parameters such as the heterogeneity τ in
the considered model. Marginal posterior expectations here result from the conditional expectations as
expected values with respect to the heterogeneity’s marginal posterior distribution p(τ |~y, ~σ), i.e.,
E[µ|~y, ~σ] = Ep(τ |~y,~σ)
[
E[µ|τ, ~y, ~σ]
]
and E[θj|~y, ~σ] = Ep(τ |~y,~σ)
[
E[θj |τ, ~y, ~σ]
]
. (12)
In both cases the conditional expectations result as convex combinations of the form
∑
i αi(τ) yi (see
Equations (4) and (10)). For convex (or, more generally, linear) combinations, we may re-write the expec-
tations as
Ep(τ |~y,~σ)
[∑
i
αi(τ) yi
]
=
∑
i
Ep(τ |~y,~σ)[αi(τ)] yi, (13)
so that it becomes apparent that the marginal expectation may again be expressed as a weighted average
of the effects yi, where the study weights now arise as the posterior expected weights. These constitute
straightforward generalizations of the common conditional weights to the Bayesian context. The weights
result as one-dimensional integrals (expectations) involving the heterogeneity’smarginal posterior distribu-
tion and may easily be computed numerically; they are returned by default by the bayesmeta R package
(Ro¨ver, 2015, 2020).
3.3 Properties
For τ = 0 the NNHM reduces to the FE model, in which all study effects θi coincide with the overall
mean µ. As τ is varied between the two extremes of τ = 0 and τ → ∞, several effects may be observed
for the conditional weights:
• The IV-weights wj(τ) move (not necessarily monotonically) from “fixed-effect” weights wj(0) =
1
σ2
j∑
i
1
σ2
i
that depend on the study’s precision towards “average” weights wi(∞) =
1
k
where all studies
have the same weight.
• The weights bj(τ) increase monotonically from 0 towards 1.
• The shrinkage weights cjj(τ) (the contribution of the jth study to its own shrinkage estimate) increase
monotonically from the FE weight towards 1.
For the conditional expectations, this implies:
• The conditional effect estimate µ˜(τ) moves from the FE estimate towards an unweighted average.
• The conditional shrinkage estimates θ˜j(τ) move from the FE estimate towards the “un-pooled” orig-
inal estimates yj .
Posterior expectations of the weights of course depend on the heterogeneity’s posterior distribution p(τ |~y, ~σ).
For a uniform effect prior, a given heterogeneity prior p(τ) and standard errors σi, the posterior density is
given by
p(τ |~y, ~σ) ∝ p(τ) f~σ(τ) g~y(τ) (14)
with
g~y(τ) = exp
(
− 12
[
(y1−µ˜(τ))2
σ2
1
+τ2
+ (y2−µ˜(τ))
2
σ2
2
+τ2
])
= exp
(
− 12
(y2−y1)2
σ2
1
+σ2
2
+2τ2
)
(15)
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(see, e.g., Eqn. (11) in Ro¨ver (2020)), where p(τ) is the heterogeneity’s prior density, and f~σ(τ) is a
lengthier term involving τ and ~σ. From (15) one can see that the heterogeneity’s posterior depends on the
data (y1, y2) only via the absolute difference |y2 − y1|, which in a sense constitutes the “empirical” or
“observed” amount of heterogeneity, through the exponential term g~y(τ).
A closer look at g~y(τ) shows that it always remains between zero and one (0 < g~y(τ) ≤ 1). For
y2 = y1, it is constant at g~y(τ) = 1. For a given difference |y2 − y1| > 0, it takes its minimum at
τ = 0 and then increases monotonically with τ . For any given τ it decreases monotonically in |y2 − y1|.
One might think of g~y(τ) as “ruling out” smaller τ values in the heterogeneity posterior and pushing the
posterior mode towards higher τ values as |y2 − y1| increases.
The functional form of the posterior (15) implies that for increasing |y2 − y1| the resulting marginal
heterogeneity posterior becomes stochastically larger (Shaked and Shanthikumar, 2007); see also the ap-
pendix for a derivation. When varying the prior distribution p(τ) in (14), we may to some extent also
predict the effect on the heterogeneity posterior: in particular, choosing a stochastically larger heterogene-
ity prior will imply a stochastically larger posterior as well (see also the appendix).
4 Bounds for the study weights
4.1 Lower bounds
The above conditions imply that we can derive bounds for the shrinkage weights. As mentioned previously,
concerns are sometimes raised that the target estimates may be overwhelmed by the source data, i.e.,
that certain weights may become too small (Weber et al., 2018). In the following, we will describe the
conditions under which we can derive lower bounds on weights, i.e., where we can make sure that weights
remain above a certain minimum. Important consequences for the weights, valid quite generally or for
certain heterogeneity priors p(τ), are derived below. Note that while we assume the standard errors σi
to be given (a common assumption to be made in meta-analysis or study design considerations), the data
(estimates yi) or the prior (p(τ)) may be varied.
4.2 A study’s minimum contribution to its own shrinkage estimate: the “FE weight”
The (conditional) shrinkage weight cjj(0), i.e. the jth study’s contribution to its own shrinkage estimate
evaluated at τ = 0, constitutes a lower bound for the posterior mean weights. Any heterogeneity prior p(τ)
may attach prior probability to τ values larger than zero, for which the weights are only increasing. These
“FE weights” may simply be computed as the common study weights in a fixed-effect meta-analysis. This
property holds independent of the actual data (yi) or the heterogeneity prior (p(τ)).
4.3 Minimum posterior mean shrinkage weight: the “coincidence weight”
For any prior distribution p(τ), the coincidence case of y1 = y2 is the data realisation yielding the lowest
possible posterior mean shrinkage weight. Any data with |y2 − y1| > 0 will imply a stochastically larger
heterogeneity posterior that will (due to monotonicity of weights cjj(τ) as a function of τ ) lead to larger
posterior mean shrinkage weights. The coincidence weights may simply be computed by performing
the meta-analysis with the data (y1 and y2) substituted by two identical numbers. This property holds
independent of the data (yi) and for any given heterogeneity prior (p(τ)).
4.4 Stochastically ordered priors and their posterior mean weights
Considering stochastically ordered families of heterogeneity priors allows to vary the posterior mean
shrinkage weight. For properly chosen stochastically smaller priors, the posterior mean may approach
the FE weight, while for stochastically larger priors the posterior mean weight may approach 100%. An
obvious, simple way to yield a stochastically ordered family of prior distributions for the heterogeneity is
c© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
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by using (or introducing) a scale parameter (Mood et al., 1974, Sec. VII.6.2). This property holds for given
data (yi) and a stochastically ordered family of heterogeneity priors (p(τ)).
5 Numerical illustration
In order to demonstrate the shrinkage weights’ properties, we consider an illustrative case motivated by a
scenario involving a log-OR endpoint, analogous to the simulation scenario discussed by Ro¨ver and Friede
(2020). For a study of size ni featuring two treatment arms and a binary endpoint, the results may be sum-
marized in a 2×2 contingency table. Assuming an even distribution of events and non-events across table
cells implies a log-OR estimate with a standard error of approximately 4√
ni
(Ro¨ver, 2020). Considering
a combination of a “small” and a “large” study with sizes n1 = 25 and n2 = 400 then leads to standard
errors of σ1 = 0.8 and σ2 = 0.2, respectively. We will then derive the smaller RCT’s shrinkage estimate
(for the study-specific effect θ1) that is of course primarily informed by y1, but supported by the external
data y2. The present case of σ1 ≫ σ2 is of course the kind of setting in which we expect to see larger gains
from shrinkage estimation, but with that, this is also the practically more relevant (and more illuminating)
setting.
For the analysis, we choose a half-normal heterogeneity prior with scale 0.5 (HN(0.5)), which consti-
tutes a conservative choice for the present scenario (Friede et al., 2017a). For illustration purposes, we also
utilize a (stochastically larger) HN(1.0) prior. We then fix the target y1 (arbitrarily) at zero and vary the
source y2 in order to investigate the effect on the resulting shrinkage estimates and weights.
Fig. 1 illustrates estimates’ and weights’ dependence on the difference between estimates (y1 and y2).
The top row of forest plots shows three example cases of (a) coinciding target and source estimates,
(b) some moderate and (c) larger discrepancy between the two; the resulting shrinkage estimate for the
target is shown in blue. The second row shows the posterior means of θ1 (solid lines) and the correspond-
ing 95% CIs (dashed lines) across the continuum of source data values. At the top of the plot the three
cases (a)–(c) are marked, and the blue lines correspond to the estimates also shown above. The red lines
show analogous estimates, but corresponding to a (stochastically larger) HN(1.0) prior. Note that “large”
|y2− y1| values (here e.g. |y2− y1| > 1.96(σ1+σ2) = 1.96) would imply non-overlappingCIs for source
and target studies (as in case (c)), which in reality may mean that estimates would not actually be pooled
at all. The practically most relevant bit of the plot is hence in the neighbourhood of zero.
The bottom plot finally shows the posterior expected weights to illustrate the first (target) study’s con-
tribution to its own shrinkage estimate. The minimum (for both heterogeneity priors) is attained in the
“coincidence case” (a) of y2 − y1 = 0; e.g., for the HN(0.5) prior the coincidence weight is at 29%.
Increasing the observed effect difference |y2 − y1| (i.e., the “observed heterogeneity”) then yields increas-
ing weights for y1, implying less borrowing from the source. In cases (b) and (c), the shrinkage weight
amounts to 38% and 63%, respectively. Also, the choice of a stochastically larger prior, here realized
by a larger scale parameter in the same familiy of distributions, leads to larger weights for y1, for any
|y2 − y1|, including the minimum at |y2 − y1| = 0. The first study’s absolute minimum shrinkage weight,
the “FE weight”, in this case is at c11(0) =
σ2
1
σ2
1
+σ2
2
= 117 = 5.9%.
Note that while “y1 = y2” constitutes a “worst case” in a certain sense (leading to the lowest shrinkage
weight), it also still is the most desirable case, in the sense that this is when the data are in agreement and
one would expect to learn the most from the source study.
6 Applications
6.1 Creutzfeldt-Jakob example
A small randomized controlled trial (RCT) was conducted in order to investigate the effect of doxycycline
on survival in patients suffering from Creutzfeldt-Jakob disease (CJD). In this ultra rare condition, only
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Figure 1 Effect of varying the difference between quoted estimates (y2 − y1) on the first shrinkage esti-
mate (for θ1). The top row shows three data examples of (a) coinciding and (b)–(c) increasingly diverging
estimates, along with the resulting shrinkage estimate for the target study. The second row illustrates the
estimates across the continuum of increasing y2 values relative to the “plain” interval (y1 ± 1.96σ1). The
bottom panel shows the posterior mean shrinkage weight (E[c11(τ)|~y, ~σ]) for the first study, based on two
different priors and for varying y2 − y1. Note that y2 − y1 = 0 constitutes the “coincidence case”.
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Table 1 Data from Varges et al. (2017) on an observational and a randomized study investigating the
effect of doxycycline on survival in Creutzfeldt-Jakob disease (CJD).
patients log(HR)
i study treatment control yi σi
1 observational 55 33 −0.499 0.249
2 randomized 7 5 −0.173 0.631
Table 2 Estimates for the CJD example. For different heterogeneity priors (HN(0.5) or HN(1.0)), the
corresponding minimum (coincidence) weight is given, as well as the resulting weight for the actual data
along with the corresponding shrinkage estimates. The very last line shows the estimate based only on y2
and σ2 for comparison.
mean weight effect estimate θ2
τ prior minimum actual mean 95% CI
HN(0.5) 38.9% 39.5% −0.370 [−1.157, 0.477]
HN(1.0) 52.1% 53.1% −0.326 [−1.232, 0.664]
(100.0% −0.173 [−1.410, 1.064])
12 patients could be recruited, and so data from an observational study were considered as complement-
ing evidence (Varges et al., 2017). Both studies quote estimated hazard ratios (HRs), and these estimates
along with their standard errors are jointly analyzed in a meta-analysis; the data are also shown in Ta-
ble 1. With the focus being on the evidence from the RCT, a shrinkage estimate for this study is derived
(Ro¨ver and Friede, 2020). Both studies are in agreement, suggesting a beneficial treatment effect, while
the absolute effect magnitude is larger for the observational data.
Since the larger observational study provides a much more precise estimate (smaller standard error),
one might fear that the randomized evidence will be overwhelmed by the external data in a joint analysis.
The FE weight in this case amounts to c22(0) =
σ2
2
σ2
1
+σ2
2
= 13.5%; this would be the RCT’s weight in an
FE analysis, and it constitutes a lower bound on the RCT’s weight for any data realization (y1, y2) or any
heterogeneity prior (p(τ)).
For a log-HR, we may then assume a half-normal prior with scale 0.5 (HN(0.5)) for the heterogeneity
(Friede et al., 2017a; Ro¨ver and Friede, 2020). For this prior, we get a minimum posterior mean weight
(coincidence weight) for the randomized study of 38.9%, which may already be considered reassuringly
large, in view of the sample sizes involved and compared to the FE weight. Any data realization (y1, y2)
will hence yield an eventual weight ≥ 38.9% for the RCT. Also, a larger scale of the heterogeneity prior
(i.e., a larger expected amount of heterogeneity) will increase the minimum weight for y2; e.g., a HN(1.0)
prior would yield a minimum expected shrinkage weight of 52.1%. For the actual data (Table 1), we then
get a weight of 39.5%, slightly above the minimum, for the RCT. Table 2 shows weights and estimates
corresponding to the two different heterogeneity priors. In both cases, the actual weights are not far from
their minimum value, and for both analyses there is a sizeable gain in precision for the shrinkage estimate
when compared to the original estimate (y2, σ2) alone.
6.2 Metabolic acidosis example
A gynaecological RCT investigated whether fetal monitoring using cardiotocography (CTG) combined
with ECG ST-segment analysis (ST) reduced the occurrence of metabolic acidosis, compared to CTG alone
(Westerhuis et al., 2007). Here the relative risk (RR) of metabolic acidosis comparing the two treatment
c© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
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Table 3 Data from Rietbergen et al. (2011) on two gynaecological RCTs investigating whether fetal
monitoring using cardiotocography (CTG) combined with ECG ST-segment analysis was associated with
a reduced risk of metabolic acidosis, compared to CTG alone.
treatment control log(RR)
i study events total events total yi σi
1 Amer-Wa˚hlin (2001) 15 2159 31 2079 −0.764 0.313
2 Westerhuis (2007) 20 2827 30 2840 −0.401 0.287
Table 4 Estimates for the metabolic acidosis example. For different heterogeneity priors (HN(0.5) or
HN(1.0)), the corresponding minimum (coincidence) weight is given, as well as the resulting weight for
the actual data along with the corresponding shrinkage estimates. The very last line shows the estimate
based only on y2 and σ2 for comparison.
mean weight effect estimate θ2
τ prior minimum actual mean 95% CI
HN(0.5) 72.5% 74.0% −0.495 [−0.986, 0.005]
HN(1.0) 78.7% 80.5% −0.472 [−0.983, 0.051]
(100.0% −0.401 [−0.964, 0.163])
groups is of interest. When analyzing the data, evidence from an earlier, similar RCT (Amer-Wa˚hlin et al.,
2001) may be utilized to support parameter estimation. This example data set was originally investigated
by Rietbergen et al. (2011); the corresponding data are shown in Table 3.
Primary interest focuses on the more recent target study by Westerhuis et al. (2007) and on a shrinkage
estimate of its study-specific effect θ2. The two trials are of roughly comparable size (5667 vs. 4238
participants), and from the “FE weight” of c22(0) =
σ2
2
σ2
1
+σ2
2
= 54.3% one can already see that the second
study will definitely contribute the majority of weight when estimating its own effect θ2.
For a log-RR, we may again use a half-normal prior with scale 0.5 for the heterogeneity (Friede et al.,
2017a); this yields a minimum (coincidence) mean shrinkage weight of 72.5%. A larger heterogeneity
prior scale again leads to an increased shrinkage weight; e.g., for a HN(1.0) prior, the minimum weight is
at 78.7%. Table 4 shows the corresponding weights and estimates. Compared to the previous example, the
precision gain is not quite as large here.
7 Conclusions
Bayesian meta-analysis provides a transparent means for extrapolation or borrowing of strength from ex-
ternal data (Ro¨ver and Friede, 2020). Also within a Bayesian inference framework, study weights for
overall and shrinkage effect estimates may be derived as posterior expected weights, for any number of
studies k. The FE weights (conditional on τ = 0) constitute the absolute minimum shrinkage weights
across all heterogeneity priors and data realizations. In case of k= 2 studies, the heterogeneity posterior
depends on the data only via the absolute difference in both estimates (|y2− y1|). A larger difference leads
to a stochastically larger heterogeneity posterior. When the estimates coincide, i.e. y2 = y1, the smallest
possible shrinkage weight for a given heterogeneity prior (across all possible data realizations) is obtained.
Concerning the choice of heterogeneity prior, a stochastically larger prior leads to a stochastically larger
posterior, and with that to increased (minimum and actual) shrinkage weights.
The above findings have important implications for the weightings that may occur within a meta-
analysis. The shrinkage weight is bounded below (irrespective of the prior and data) by the FE weight. For
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any particular given prior, the (posterior mean) shrinkage weight is also bounded below across possible
data realisations by the “coincidence weight”. Having a bound on the weight effectively means bounding
the “leverage” of the external data for the shrinkage estimate. A lower bound of, say, 50% means that the
resulting shrinkage estimate will not move more than halfway from the effect yi towards the external data
(in case of concordant evidence; otherwise even less).
The FDA Guidance on “Leveraging existing clinical data for extrapolation to pediatric uses of medical
devices”(U.S. Department of Health and Human Services (HHS), Food and Drug Administration (FDA), 2016)
for example elaborates on issues commonly encountered in extrapolation endeavours. One concern raised
here is the exchangeability assumption (3) commonly made in hierarchical models. In the common case of
only k=2 studies, however, the same model (as far as shrinkage estimation is concerned) may alternatively
be motivated via the reference model (Ro¨ver and Friede, 2020). This is similar to the bias allowance model
framework (Welton et al., 2012), where the target study is estimating the parameter of interest “directly”,
while the source is associated with a potential bias term of unknown direction and magnitude. Moreover,
the advantages of using (informative) priors on the heterogeneity parameter are acknowledged in the guid-
ance document, in particular as this facilitates dynamical borrowing based on the empirically observed
compatibility of source and target data.
We would like to encourage consideration of minimum weights as a diagnostic tool of the evidence
constitution and of implications of prior settings for a given or anticipated data scenario. The study of
weights should, however, not be used for guiding the selection of the heterogeneity prior. The choice
of prior should of course primarily be driven by considerations of prior information on between-study
variability.
The considerations which provide some insights into the inner workings of shrinkage estimation facil-
itate diagnostics even before considering actual data. Fears of external evidence “overruling” the target
data (Weber et al., 2018) may be unwarranted, or may be checked before carrying out the target study, as
the NNHM behaves predictably and reasonably within a Bayesian framework. Potential problems arise or
are amplified when using frequentist methods: the concerningly common occurrence of zero heterogeneity
estimates means that analyses may fall back to an FE approach, which here is the least cautious or least
conservative analysis. For the case of few studies, the probability of obtaining a zero heterogeneity estimate
is alarmingly high — approaching 50% even for moderate amounts of heterogeneity (Friede et al., 2017a),
which may actually render frequentist heterogeneity estimation for small k a somewhat questionable exer-
cise. In summary, with the target study’s contribution to the resulting Bayesian shrinkage estimate being
bounded below, concerns of evidence being easily overwhelmed by external source data can be addressed
a-priori, and may be shown to be largely unwarranted.
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A Appendix
A.1 Stochastic ordering of heterogeneity posteriors
Consider two parameter sets ~ya and ~yb for which 0 ≤ |ya;2 − ya;1| < |yb;2 − yb;1|. Then the ratio of the
heterogeneity’s marginal posterior densities is given by (cf. (14))
p(τ |~yb, ~σ)
p(τ |~ya, ~σ)
=
c~yb p(τ) g~yb(τ)
c~ya p(τ) g~ya(τ)
=
c~yb
c~ya
g~yb(τ)
g~ya(τ)
∝
g~yb(τ)
g~ya(τ)
, (16)
where c~ya and c~yb are the densities’ normalizing constants, and the where the latter ratio of “g~y(τ)” terms
is monotonically increasing in τ . With that, condition (C) in Lehmann (1955) is fulfilled, and the posterior
corresponding to ~yb is stochastically larger than the one associated with ~ya.
A.2 Stochastic ordering of posteriors for different priors
Consider two heterogeneity priors with densities p1(τ) and p2(τ) where p2 is stochastically larger than p1.
A posterior distribution constitutes a special case of a “weighted distribution” (Me¸czarski, 2015). For
the posterior distributions corresponding to p1 and p2 follows that these will inherit the same stochastic
ordering (Bartoszewicz and Skolimowska, 2006).
A.3 R code for CJD example
# specify data:
cjd <- cbind.data.frame("study" =c("observational", "randomized"),
"logHR" =c(-0.499, -0.173),
"logHR.se"=c(0.249, 0.631))
# analyze:
library("bayesmeta")
bm <- bayesmeta(y=cjd$logHR, sigma=cjd$logHR.se, labels=cjd$study,
tau.prior=function(t){dhalfnormal(t, scale=0.5)})
# show posterior mean shrinkage weights:
bm$weights.theta
# show shrinkage estimates:
bm$theta
# derive FE weights (percentages, using "metafor" library):
weights(rma.uni(yi=cjd$logHR, sei=cjd$logHR.se, slab=cjd$study,
measure="GEN", method="FE"))
# alternatively, compute directly:
cjd$logHR.seˆ-2 / sum(cjd$logHR.seˆ-2)
# determine coincidence (minimum) posterior mean weights:
bayesmeta(y=c(0,0), sigma=cjd$logHR.se, labels=cjd$study,
tau.prior=function(t){dhalfnormal(t,scale=0.5)})$weights.theta
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